Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

Table 3 Anti-dementia medication

	ATC ^a	Study population^b N (%)	Dementia diagnoses^c		P-value	Clinical signs^d of DLB		P-value	Age groups^e		P-value
	ATC ^a	Study population^b N (%)	Yes N (%)	No N (%)		0–1^\|\| N (%)	2–4^\|\| N (%)		≤85 years N (%)	≥86 years N (%)
Anti-dementia drugs (All)	N06D	192 (33.3)	192 (45.0)	0 (0.0)	***	149 (32.5)	43 (36.8)		104 (43.0)	88 (26.3)	***
ChEI (Any) ^f	N06DA	123 (21.4)	123 (28.8)	0 (0.0)	***	104 (22.7)	19 (16.2)		67 (27.7)	56 (16.8)	**
Donepezil	N06DA	42 (7.3)	42 (9.8)	0 (0.0)	***	41 (8.9)	1 (0.9)	***	19 (7.9)	23 (6.9)
Rivastagmin	N06DA	31 (5.4)	31 (7.3)	0 (0.0)	***	21 (4.6)	10 (8.5)		25 (10.3)	6 (1.8)	***
Galantamin	N06DA	50 (8.7)	50 (11.7)	0 (0.0)	***	42 (9.2)	8 (6.8)		23 (9.5)	27 (8.1)
Memantin	N06DX	100 (17.4)	100 (23.4)	0 (0.0)	***	69 (15.0)	31 (26.5)	**	59 (24.4)	41 (12.3)	***
ChEI & Memantin	N06DA N06DX	31 (5.4)	31 (7.3)	0 (0.0)	***	24 (5.2)	7 (6.0)		22 (9.1)	9 (2.7)	***

^aAnatomical Therapeutic Chemical (ATC) Classification System
^bAll participants: 610 (100%), with registered medical lists for 575 (94%) participants
^cDementia diagnoses: there were (N = 440) with a dementia diagnosis and (N = 154)participants without a dementia diagnosis
^dClinical signs: visual hallucinations, fluctuating cognition, parkinsonism and REM sleep behaviour disorder
^eAge group total 610 (100%): ≤85 years (N = 259) and ≥86 years (N = 351)
^fChEI: cholinesterase inhibitor
*P-value < 0.05, **P-value< 0.005, ***P-value < 0.001

ISSN: 1471-2318